<DOC>
	<DOCNO>NCT00152256</DOCNO>
	<brief_summary>The objective study determine safety efficacy effect two dos asoprisnil ( 10 mg 25 mg ) compare placebo administer daily 6 month premenopausal subject symptomatic uterine leiomyomata .</brief_summary>
	<brief_title>A Study Evaluate Safety Effectiveness Asoprisnil Treating Women With Uterine Fibroids</brief_title>
	<detailed_description>No medical therapy currently available long-term treatment abnormal uterine bleeding associate uterine fibroid . Asoprisnil ( 10 mg 25mg ) evaluate Phase 3 program establish long term safety effectiveness therefore provide woman medical alternative surgery .</detailed_description>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<mesh_term>Menorrhagia</mesh_term>
	<mesh_term>Metrorrhagia</mesh_term>
	<criteria>Premenopausal woman History regular menstrual cycle ( 2142 day ) Diagnosis uterine fibroid ( ) Abnormal vaginal bleeding associate uterine fibroid Otherwise good health Subject must least one fibroid diameter ≥ 2 cm multiple small fibroid uterine volume ≥ 200 cm3 Less 3 month postpartum postlactation Previous myomectomy within 1 year Any abnormal lab procedure result studydoctor considers important Severe reaction ( ) currently use hormone therapy History osteoporosis bone disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>53 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Symptomatic Uterine Fibroids</keyword>
	<keyword>Excessive Uterine Bleeding</keyword>
	<keyword>Uterine Hemorrhage</keyword>
</DOC>